Brit Mollenhauer, MD, University Medical Center Göttingen, Göttingen, Germany, discusses the current status of biomarkers used for Parkinson’s disease diagnosis. Currently, fluid biomarkers are only a research tool and not ready for clinical use. Biomarkers that could be useful are tau for Alziheimer's disease to identify cognitive decline and metabolic factors such as fasting glucose. However, there is the need for a biomarker to identify which patients are progressing faster. There is not currently a good panel of biomarkers, but the basis for research is there. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).
